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Abstract  
Objective: Mephedrone has been recently made illegal in Europe, but little empirical evidence is 
available on its impact on human cognitive functions. We investigated acute and chronic effects 
of mephedrone consumption on drug-sensitive cognitive measures, while also accounting for the 
influence of associated additional drug use and personality features.  
Method: Twenty-six volunteers from the general population performed tasks measuring verbal 
learning, verbal fluency and cognitive flexibility before and after a potential drug-taking 
situation (pre- and post-clubbing at dance clubs, respectively). Participants also provided 
information on chronic and recent drug use, schizotypal (O-LIFE) and depressive symptoms 
(Beck depression inventory), sleep pattern and premorbid IQ. 
Results: We found that i) mephedrone users performed worse than non-users pre-clubbing, and 
deteriorated from the pre-clubbing to the post-clubbing assessment, ii) pre-clubbing 
cannabis and amphetamine (not mephedrone) use predicted relative cognitive attenuations, 
iii) post-clubbing, depression scores predicted relative cognitive attenuations, and iv) 
schizotypy was largely unrelated to cognitive functioning, apart from a negative relationship 
between cognitive disorganisation and verbal fluency. 
Conclusion: Results suggest that polydrug use and depressive symptoms in the general 
population negatively affect cognition. For schizotypy, only elevated cognitive 
disorganisation showed potential links to a pathological cognitive profile previously 
reported along the psychosis dimension.  
 
Keywords: New-wave drugs, mephedrone, cognition, psychosis spectrum, substance 
dependence, cathinone 
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Introduction 
Drugs are feared to threaten our mental health facilitating politics that criminalise their 
distribution and use (Nutt et al., 2010). While we increasingly know about the clinical, cognitive, 
and physical implications when individuals use “conventional” licit and illicit psychoactive 
substances (Fernández-Serrano et al., 2011, e.g. heroine, cocaine, nicotine; Fernandez-Serrano et 
al., 2010, Nutt et al., 2010), we are yet to accumulate a comparable knowledge on so called “new 
wave” designer drugs. New wave designer drugs encompass a range of modern psychoactive 
substances, which have been both specifically marketed and synthesized for the aim of providing 
an intoxicating high. Since they are new, legislations have not yet been established, making the 
use of many of these substances officially legal and therefore attractive (Dargan et al., 2010). 
The most popular of these drugs are based on the substance cathinone, a compound found in the 
khat plant (see Schifano et al., 2010 for overview). One derivate of cathinone is a substance 
widely referred to as mephedrone, (colloquially  known as “4-MMC, MMCat, Meow/Miaow 
Miaow, Bubbles, Meph, Rush, Drone, Plant Feeder”) which has been relatively popular in the 
clubbing scene in recent years (Winstock et al., 2011, Wood et al., 2012).  
Cathinone substances have a chemical structure similar to amphetamine (Hoffman and Al'Absi, 
2010, Dal Cason et al., 1997, Prosser and Nelson, 2012), a similarity that is also reflected in the 
observation that they seem to mimic the physiological and psychological actions of 
amphetamines (Kalix, 1992, Schifano et al., 2010). For instance, both cathinones and 
amphetamines prevent the uptake and stimulate the presynaptic release of dopamine, serotonin 
and noradrenalin (see Kalix, 1992 for overview). Importantly, similarly to amphetamines, high 
doses of mephedrone can induce hallucinations (ACMD, 2010, Vardakou et al., 2011, James et 
al., 2010). To assess the physiological and psychological effects of cathinones, Brenneisen et al. 
Page 3 of 45
http://mc.manuscriptcentral.com/hup
Human Psychopharmacology: Clinical and Experimental
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 4
(1990) investigated the effects of intravenous administration of cathinone in human participants 
and discovered that the drug markedly increased heart rate and blood pressure in comparison to 
placebo. Furthermore, participants reported an increased sense of euphoria and sociability, which 
is comparable to independent reports on the psychological effects of mephedrone (Morris, 2010). 
Reports such as these  facilitated a fierce debate on the potential risks and harmfulness of 
mephedrone, and its use was recently made illegal in the UK (see Vardakou et al., 2011 for 
overview, Winstock et al., 2011) and other European countries (EMCDDA, 2010a, EMCDDA, 
2011, EMCDDA, 2012). 
Despite some scientific explorations on the physiological and psychological effects of cathinones 
(Brenneisen et al., 1990, James et al., 2010, Vardakou et al., 2011, ACMD, 2010, Morris, 2010, 
Wood and Dargan, 2012), studies on the cognitive effects of these substances are surprisingly 
sparse (Hoffman and Al'Absi, 2010), and to our knowledge have only recently started to be 
investigated. For instance, khat use has been found to relate to impairments in working 
memory and cognitive flexibility (Colzato et al., 2011b), increased response conflict 
(Colzato et al., 2012) and decreased inhibitory control (Colzato et al., 2011a). Given the 
similarities between amphetamines and cathinones in chemical structure (Dal Cason et al., 1997) 
and subjective reports (Brenneisen et al., 1990, James et al., 2010, Vardakou et al., 2011, 
ACMD, 2010, Morris, 2010, Wood and Dargan, 2012), it seems justified to expect cathinone use 
to result in similar cognitive peculiarities to those reported after amphetamine use. If this 
reasoning is indeed considered feasible, we can infer from previous experimental research into 
the cognitive harms of amphetamines (see Fernández-Serrano et al., 2011, Kalechstein et al., 
2007 for overview) that mephedrone (and other derivates of cathinones) might negatively affect 
various aspects of cognition such as working memory (Curran and Travill, 1997), verbal fluency 
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(Hanson and Luciana, 2004), cognitive flexibility (King et al., 2010), verbal learning (Gonzalez 
et al., 2004, Laws and Kokkalis, 2007, McCardle et al., 2004, Parrott and Lasky, 1998), and 
mood (Curran and Travill, 1997, Parrott and Lasky, 1998). Given that these predictions are based 
on inferences from research on amphetamines, we here aimed to test more directly whether 
cognitive impairments reported from amphetamine use might also be observed for mephedrone 
use or other drug use more broadly.  
While the question on cognitive impairments as a function of drug use seems straightforward, it 
misses out on the equally important question on who would be most prone to use such drugs in 
the first place, or who might have a higher risk of experiencing harmful consequences from drug 
consumption. Knowing about these influential factors should indeed be of interest to clinicians 
and society more broadly, because early detection might help reduce negative long-term 
consequences for mental health (Bird et al., 2010, Marshall and Rathbone, 2006, Larsen et al., 
2011). One factor associated with enhanced drug use is schizotypy (see Barkus and Murray, 
2010 for overview), a personality construct that has also been associated with an enhanced risk 
for psychiatric conditions (Chapman et al., 1994, Gooding et al., 2005).  
Schizotypy is thought to describe subjective experiences in the general population that are 
reminiscent of those reported from patients with schizophrenia, but in a milder form (Meehl, 
1962). Such similarities are not only evident on the phenomenological level, but are also found 
for cognitive functions. In more detail, cognitive impairments that are common in patients with 
psychosis are also found along the psychosis dimension, although less severe, such as in 
individuals with a schizotypal personality disorder [see Reichenberg & Harvey (2007) for 
overview], and individuals from the general population scoring relatively high on self-report 
schizotypy questionnaires (Krabbendam et al., 2005, Poreh et al., 1995, Burch et al., 2004, 
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Laurent et al., 2001, Vollema and Postma, 2002). Most important to the present study, cognitive 
functions relying on the frontal lobes such as cognitive flexibility (Diforio et al., 2000, Laurent et 
al., 2000, Voglmaier et al., 1997, Blanchard et al., 2010), working memory (Voglmaier et al., 
1997, Voglmaier et al., 2005, Park and McTigue, 1997, Kopp et al., 2002), verbal memory 
(Kaczorowski et al., 2009, Burch et al., 2006) and verbal fluency (Laurent et al., 2000, 
Tsakanikos and Claridge, 2005) seem attenuated along the psychosis spectrum including 
schizotypy (see also Reichenberg and Harvey, 2007 for overview).  
A potential problem of the above described literature is that only few investigated cognition, 
drug use and schizotypy simultaneously, i.e. studies either investigated the influence of a 
particular drug on cognition, the link between drug use and schizotypy, or the relationship 
between schizotypy and cognitive functioning. Yet, in the latter case, individuals with elevated 
schizotypy are also likely to be subject to relative enhanced polydrug use, without this drug 
consumption being accounted for. We found 14 studies investigating the link between 
schizotypy and cognitive flexibility, verbal memory and verbal fluency; seven of them did 
not report on drug use (Laws et al., 2011, Giraldez et al., 1999, Dinn et al., 2002, Lenzenweger 
and Korfine, 1994, Park et al., 1995, Tsakanikos and Claridge, 2005, Burch et al., 2006), and the 
others varied in their drug control criteria  (Poreh et al., 1995, Daneluzzo et al., 1998, Kim et al., 
2011, Suhr, 1997, Koychev et al., 2011, Kaczorowski et al., 2009, Matheson and Langdon, 
2008). It is thus possible that substance use (e.g. illicit as well as licit substances) influenced the 
relationship between schizotypal symptoms and the cognitive functions assessed (Herzig et al., 
2010, Herzig and Mohr, 2012). As will be shown in the following, the present study took this 
reasoning into account.  
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We investigated the potential role of current mephedrone use (but also of other common drugs) 
on cognitive functioning, and how this relationship might be influenced by individuals’ 
schizotypy. In particular, we adopted a “natural” design in which a group of participants was 
tested twice, before (pre-clubbing) and after (post-clubbing) their clubbing experience. Because 
mephedrone was a preferred clubbing drug at the time of testing, we expected that some 
participants would consume new wave designer drugs such as mephedrone. This experimental 
design not only allowed to account for changes of cognitive functioning over the course of a 
clubbing experience (short-term) but also whether individuals using mephedrone have a more 
severe overall drug history (polydrug use) potentially implying that their cognitive functioning is 
already relatively impaired at the pre-clubbing stage (long-term effects).  
Given the similarity between the physiological and emotional effects of cathinones and 
amphetamines, we predict that mephedrone users as compared to non-users should show 
relatively impaired cognitive functioning as reported from amphetamine users (cognitive 
flexibility, verbal learning and verbal fluency). Moreover, we considered the possibility that drug 
use rather than schizotypy would be the dominant predictor of these relatively impaired cognitive 
functions (Herzig et al., 2010, Herzig and Mohr, 2012). Because of the reported links between 
various drugs of abuse, mood and sleep patterns on cognition we also controlled for possible 
influential variables such as depression (Deykin et al., 1987, Davison and Parrott, 1997, Curran 
and Travill, 1997, MacInnes et al., 2001) and sleep (Curran and Travill, 1997, Carhart-Harris et 
al., 2008). By accounting for these variables a ‘purer’ measure of the effects of drug use on 
cognition is expected to derive. 
Methods 
Participants 
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Participants were recruited using a combination of snowballing sample method and 
advertisements, distributed at local businesses and university departments in the Bristol area. It 
was made explicitly clear that only members of the clubbing community (those going to dance 
clubs) were eligible to take part in the study, although no mention was made of drug use. 
Participants were excluded if they reported any major psychiatric illness or chronic health 
problems. Furthermore, participants were excluded if they were currently taking psychoactive 
medication (such as antidepressants, analgesics or neuroleptics), and/or had suffered from any 
form of organic head injury according to self-report. No pressure was placed on participants to 
consume psychoactive drugs at any point during the research, and no reimbursement was given 
for participants’ time. Instead, they were entered into a prize draw to win £100 worth of vouchers 
to spend in a Bristol based business enterprise. We were able to recruit 26 native English 
speakers (all educated to at least degree level) who were willing to participate shortly before 
and after their clubbing experience. All participants provided written informed consent. The 
study was approved by the ethics committee of the University of Bristol, Department of 
Experimental Psychology. 
Procedure 
Participants completed a total of two experimental sessions, lasting approximately an hour each. 
The pre-clubbing session took place (mostly) on the Friday, in a quiet laboratory in the 
Department of Experimental Psychology, University of Bristol. This session acted as a baseline 
for measuring participants’ cognitive performance when abstinent from current psychoactive 
drugs (baseline cognitive functioning). Drug use information was not analysed during this 
session, rendering the experimenter blind to participants’ drug history. During this session 
participants completed all of the cognitive tasks and questionnaires (details are given below). 
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Following completion of these tasks participants were instructed to engage in their usual 
clubbing experience. It is important to note that participants were not aware that the study was 
assessing the link between mephedrone use and cognition, therefore preventing to stimulate 
participants’ motivation to consume drugs to be eligible for this study. The post-clubbing session 
was arranged approximately 48 hours after the night that they went clubbing (e.g. if they went 
clubbing on Friday the next testing session would be on Sunday). Participants were considered 
mephedrone users if they reported mephedrone use in the 48 hours between the pre-clubbing and 
post-clubbing testing sessi n. The post-clubbing testing session involved exactly the same 
cognitive measures and tests that were completed in session 1. Considering the likely polydrug 
use of clubbers, participants also filled out additional questionnaires that measured their current 
and past psychoactive drug use (including any drugs taken in the period between testing 
sessions).  
Tasks 
Cognitive tests
1
 
Premorbid verbal intelligence: The national adult reading test (NART) 
To ensure groups were matched on IQ, participants completed the NART at the beginning of the 
pre-clubbing session. The NART is designed to provide a measure of verbal IQ, through the 
visual presentation of a list containing 50 irregular words, which the participant is required to 
pronounce in serial order (Nelson, 1982). The NART is a widely used and reliable test that takes 
advantage of the correlation between reading ability and intelligence in the normal population 
(Wiens et al., 1993). The greater the number of correctly pronounced words the higher a 
                                                 
1
 We measured a computerised Go NoGo task as well. Due to an overall ceiling performance, we omitted this task 
from all further analysis. Detailed information on this task can be requested from the first author.  
Page 9 of 45
http://mc.manuscriptcentral.com/hup
Human Psychopharmacology: Clinical and Experimental
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 10 
participant’s verbal IQ. Normative values for the English version in healthy adults can be found 
in Crawford et al. (1989). 
 
Verbal learning and memory:  The Rey Auditory verbal memory task (RAVLT)  
The RAVLT (e.g. Spreen and Strauss, 1998) is an easy to administer task assessing verbal 
learning as well as immediate and delayed recall. A series of 15 nouns are read aloud to the 
participant (separated by one second intervals) for five consecutive trials. Each trial is followed 
by an immediate free recall test. We assessed the number of correctly recalled words over the 
five trials (maximum 75). Finally, after a delay of 25 minutes, participants were again asked to 
recall the original word list (delayed recall). We calculated percentages of the correctly recalled 
words for both immediate and delayed recall. Pre-clubbing and post-clubbing, participants 
received alternative versions with the order of the two versions  counterbalanced between 
participants. Normative values for both versions can be found in Badcock et al. (2011). 
Verbal fluency (COWAT) 
The COWAT (Controlled Word Association Task) was originally developed by Bechtold, 
Benton et al. (1962), and is a measure of left frontal lobe functioning (Newman et al., 2007, 
Wood et al., 2001). It tests participants’ ability to produce as many words as they can that begin 
with pre-determined sequentially presented letters (in this study: F, A and S) or categories (in 
this study: animals, vegetables and fruit) within a minute. In the present study, only letters were 
presented. We assessed the number of correctly generated words across all three letters. Proper 
nouns and changing of suffixes and prefixes were not included (for example ‘See’ would be 
correct but subsequently saying ‘seeing’ would not). The test has been found to have reasonable 
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test-retest reliability (Ruff et al., 1996), and updated normative data can be found in Ruff et al. 
(1996). 
Trail making task (TMT) 
The TMT is used to test cognitive flexibility. It was originally part of the Army Individual Test 
Battery (1944), and was incorporated into the Halstead–Reitan Battery (Reitan and Wolfson, 
1985). In the TMT participants are presented with a sheet of paper depicting circles. These 
circles are either filled with numbers (TMT A), or with numbers and letters (TMT B). In version 
A, participants have to draw a line from circle 1 to circle 25 in chronological order, as fast as 
possible. In TMT B participants have to draw a line in chronological order from 1 to 13, and A to 
L, but to switch back and forth between numbers and letters. Therefore, participants draw a line 
from 1 to A, from A to 2, from 2 to B etc. The reaction time (RT) of both tasks are recorded, and 
an index subtracting RT’s of TMT A from RT’s of TMT B results in an estimate of cognitive 
flexibility (Lezak, 1995) adjusted for individual differences in motor functioning and visual 
search strategies (Reitan and Wolfson, 1985). Norm values are available from Tombaugh (2004). 
 
Questionnaires 
The Beck Depression Inventory (BDI) 
The BDI (Beck et al., 1961) is a 21 item questionnaire designed to measure depressive 
symptoms. Each item comprises a 4 choice statement differing in the extent of depressive 
loading. For example (0) I don’t have thoughts of killing myself, (1) I have thought of killing 
myself but I would not carry them out, (2) I would like to kill myself, (3) I would kill myself if I 
had the chance. Each of the 4 choice statements provides a score that indicates how depressed 
the person feels from 0 to 3. The total depression score is the sum of the scores of each of the 21 
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items. Scores between 0–9 indicate that a person is not depressed, 10–18 indicates mild-
moderate depression, 19–29 indicates moderate-severe depression and 30–63 indicates severe 
depression (Sotiropoulos et al., 2008, Beck et al., 1961). In this experiment, we asked 
participants to answer the questionnaire by referring to how they generally felt in the past two 
weeks (pre-clubbing) and to how they feel currently (post-clubbing). 
The Oxford-Liverpool Inventory of Feelings and Experiences (O-LIFE; short version) 
The short O-LIFE questionnaire (Mason et al., 2005) is a validated 43-item self-report 
questionnaire assessing schizotypy in terms of four dimensions. Positive schizotypy is assessed 
by 12 items pertaining to Unusual Experiences (UnEx, maximum score 12, including items such 
as ‘Are your thoughts sometimes so strong that you can almost hear them?’), negative schizotypy 
is assessed by 10 items pertaining to Introvertive Anhedonia (IntAn, maximum score 10, 
including items such as ‘Do you prefer watching television to going out with people?’), and 
Cognitive Disorganization is assessed by 11 items (CogDis, maximum score 11, including items 
such as ‘Are you easily confused if too much happens at the same time?‘). Finally, 10 items 
assess Impulsive Nonconformity (ImpNC, maximum score 10), which does not represent a 
schizotypy dimension (Mason et al., 1995), but will be accounted for in the present study 
because of the significant link between impulsivity and addiction (Crews and Boettiger, 2009). 
For each item, participants have to indicate whether the statement is true or false. The number of 
positive responses (some items are reversely formulated) is summed so that higher scores 
indicate higher schizotypy. Normative values can be found in Mason et al. (2005) and the scale 
has shown good internal consistency as well as high correlations with the original O-LIFE 
questionnaire (Mason et al., 2005, Mason et al., 1995). 
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Drug use and sleep patterns 
On the post-clubbing testing session participants were asked to fill in the drug questionnaires of 
the national household survey on drug abuse (NHSDA; 1998). The NHSDA questionnaire gives 
detailed data of respondents’ prior drug use, and an adapted version was administered to assess 
use of nicotine, alcohol, cannabis, mephedrone, amphetamine, cocaine, ketamine and 
benzodiazepine use during the clubbing experience (amount used), and in the past 30 and seven 
days (times used). Additionally, participants indicated their total amount of average hours of 
sleep, as well as how much they slept between the pre- and the post-clubbing experience (total 
amount of hours).  
 
Data analysis Mephedrone use vs. Control 
In a first set of analysis, in which we focused on recent mephedrone use, we calculated separate 
2 x 2 mixed sample ANOVAs with day (pre-clubbing, post-clubbing) as the related samples 
factor and drug use group (mephedrone, control) as the independent samples factor on the total 
% correct responses in the RAVLT (measuring verbal learning) as well as total amount correct 
items named in the COWAT (measuring verbal fluency). In the TMT (measuring cognitive 
flexibility) an index (TMT B –TMT A) was calculated and used as an outcome measure, with 
higher values indicating reduced cognitive flexibility. Post-hoc tests were performed using paired 
samples tests. Effect sizes are reported for all ANOVA results.  
In order to establish if schizotypy explained an additional amount of variance on top of drug use 
and demographic / control variables, we firstly explored which variables are relevant to the 
regression models. We correlated age, BDI scores, hours of sleep (average and total hours 
between pre- and post-clubbing), NART-scores, drug use variables and schizotypy sub-scale 
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scores with the outcome measures of the cognitive tasks. For regression analyses, we only kept 
variables that were significantly related to at least one outcome measure. Subsequently, two 
separate regression models were run, corresponding to the two times of assessment (see result 
section for details). Blocks of predictors were entered into the regression model, with the first 
one containing control variables (if none of these correlated with the outcome measures, this step 
was omitted), the subsequent step including drug use information, and the final step containing 
schizotypy measures. These blocks were entered in nested blocks, meaning that each subsequent 
block contained all prior predictors and the additional predictors from the current block. 
Presentation of results however will only include significant predictors as in Fridberg et al. 
(2011), for economy of presentation. Because all tolerance values were above .2 (Menard, 1995), 
and all independent variables were mean-centered, multi-collinearity between the independent 
variables was considered negligible. The dependent variables were i) total percentage correctly 
recalled items in the RAVLT, for immediate and delayed recall, ii) the total amount of correctly 
named items in the verbal fluency task, and iii) TMT index scores.  
Kolmogorov–Smirnov tests for the groups separately revealed normal distribution for all 
behavioral measures, NART, BDI and schizotypy scores. All p-values were two-tailed and the α-
level was set at .05.  
 
Results 
Participants and self-report questionnaires 
The first major analysis concerned the grouping of people in the mephedrone and control group. 
Of the 26 participants, 10 reported having used mephedrone between test sessions.  
Page 14 of 45
http://mc.manuscriptcentral.com/hup
Human Psychopharmacology: Clinical and Experimental
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 15 
In the 30 days prior to testing, eight of the 10 mephedrone users reported having used nicotine, 
one had used cannabis, eight had used alcohol, and four had used amphetamines. In the 30 days 
prior to testing, 14 of the 16 non-mephedrone using controls used alcohol, four had used 
cannabis and five had used nicotine.  
In the seven days prior to testing, only one mephedrone user had used amphetamines and 
cannabis once. For all other mephedrone users recency of use for other illicit substances 
(including mephedrone) exceeded seven days. None of the mephedrone non-users had used 
cannabis or other illicit substances within the last seven days prior to testing.  
As is evident from Table 1, mephedrone users used more amphetamine, mephedrone, and 
nicotine as compared to the control group in the past 30 days, more nicotine in the past seven 
days prior to testing, and more mephedrone and alcohol during the clubbing experience. 
Furthermore, mephedrone users as compared to controls scored higher on BDI scores, CogDis 
and ImpNC. A mixed-samples ANOVA with BDI scores pre-clubbing and post-clubbing as the 
repeated measures, and group (mephedrone, control) as the between subjects factor indicated that 
there was a significant effect of day of testing [F(1,24)=6.69, p=.02, partial η
2
= .22], with BDI 
scores being generally lower pre-clubbing than post-clubbing (see Table 1). There also was a 
significant interaction between group * day of testing [F(1,24)=17.83, p<.001, partial η
2
= .43]. 
Post-hoc paired samples t-tests split by group revealed that this rise in BDI scores was only 
significant in the mephedrone using group [t(9)=-3.70, p<.01], but not in the control group 
[t(15)= 1.50, p=.16; see Table 1]. All other measures did not differ between groups (Table 1). 
 
-Table 1 about here- 
 
Results in the behavioural tasks 
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RAVLT  
For the immediate recall measure, we found that mephedrone users performed worse than 
controls (F(1,24) = 10.43, p < .01, partial η
2
= .30; see Table 2). The interaction between group 
and day (F(1,24)= .85, p= .37, partial η
2
 = .03) and the effect of day (F(1,24) = 1.99, p = .17, 
partial η
2
= .08; see Table 2) were both not significant. For the delayed recall measure, we found 
that mephedrone users performed significantly worse than controls (F(1,24) = 12.33, p < .01, 
partial η
2
= .34; see Table 2). Whereas the effect of day (F(1,24) = .73, p = .40, partial η
2
 = .03; 
see Table 2) was not significant, the analysis revealed a significant interaction between group 
and day (F(1,24) = 7.72, p = .01, partial η
2
 = .24). Post-hoc paired samples t-tests split by group 
revealed that in the control group there was no difference in scores between pre- and post 
clubbing [t(15) = -1.30, p = .21]. However, the mephedrone group showed a significant decrease 
in delayed recall performance between pre- and post-clubbing [t(9) = 4.33, p < .01; see Table 2]. 
 
-Table 2 about here- 
 
COWAT 
There was a significant main effect for group (F(1,24) = 5.32, p = .03, partial η
2
= .18), with 
mephedrone users performing significantly worse than controls (see Table 2). Additionally, there 
was a significant effect of day (F(1,24) = 6.77, p = .02, partial η
2
= .22; see Table 2), and 
interaction between group and day (F(1,24) = 13.11, p < .01, partial η
2
 = .35). Post-hoc paired 
samples t-tests split by group revealed that in the mephedrone group values significantly 
decreased from pre- to post-clubbing [t(9) = 5.00, p < .01; see Table 2), whereas there was no 
day difference in the control group [t(15) = -.74, p = .47; see Table 2). 
 
TMT 
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There were no significant findings (group: F(1,24) = .39 p = .54, partial η
2
 = .02; day: F(1,24) = 
.60, p = .45, partial η
2
 = .02, interaction between group * day: F(1,24) = 1.31, p = .26, partial η
2
 
=.05; see Table 2). 
 
Regressions: Severity of drug use and schizotypy as predictors of performance 
To further investigate the possibility that schizotypy may be relevant to cognitive functioning on 
top of drug use, multivariate step-wise regressions were conducted. Exploratory correlation 
analyses (Table 3) showed that pre-clubbing amphetamine, mephedrone and cannabis use in the 
past 30 days, as well as CogDis scores correlated with cognitive functioning. Therefore, for the 
pre-clubbing session amphetamine, mephedrone and cannabis use in the past 30 days was 
entered in the first step, and CogDis scores in the second step.  
 
-Table 3 about here- 
 
For the post-clubbing session (Table 4) BDI scores, total hours of sleep between test sessions, 
mephedrone use and schizotypy scores (UnEx, CogDis and ImpNC scores) were correlated with 
at least one of the outcome measures. Therefore, BDI scores post-clubbing and total hours of 
sleep between test sessions were entered in the first step, mephedrone use between test sessions 
in the second, and schizotypy subscales (UnEx, CogDis and ImpNC) in the third step. 
-Table 4 about here- 
 
The results from the regression on pre-clubbing session are displayed in Table 5. We found that 
immediate recall in the RAVLT was reduced with increasing cannabis use and delayed recall in 
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the RAVLT was reduced with increasing amphetamine use. Additionally, increasing CogDis 
scores related to a decreasing number of words produced in the COWAT.  
-Table 5 about here- 
The results from the regression on post-clubbing session are presented in Table 6. Results 
indicate that increasing BDI scores predicted lower RAVTL performance (immediate and 
delayed recall) as well as less words produced in the COWAT. Additionally, a higher amount of 
hours slept between test-sessions related to lower immediate recall performance in the RAVTL 
and less words produced in the COWAT. Adding drugs or schizotypy in later steps did not 
explain additional variance in cognitive functioning.  
-Table 6 about here- 
 
Discussion 
Drug policies are aimed to prevent harm to people by making access to these drugs more 
difficult. To avoid the problem of the illegality of drugs, new drugs are frequently developed that 
are little or not yet regulated. Among those drugs are popular new wave designer drugs such as 
mephedrone. These provide “legal highs” without knowing much about their harmfulness or 
factors that might predict it. We here investigated whether mephedrone use might have a 
negative impact on cognitive functioning, and whether any such relationship might be influenced 
by individuals’ schizotypal features and other drug use. We tested cognitive functions that were 
formerly associated with amphetamine use and elevated schizotypy, i.e. cognitive flexibility, 
verbal learning and verbal fluency. Importantly, we were able to recruit volunteers in a “natural” 
setting, i.e. before and after a clubbing experience during which drugs such as mephedrone are 
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commonly consumed. The advantage of this design consists in the assessment of i) participants’ 
baseline functioning (i.e. the cognitive level at which individuals with different drug histories 
entered the study), and ii) how the drug use of the clubbing experience affected their cognitive 
performance (i.e. short-term effects). The main findings of the present study were that i) 
mephedrone users performed worse than controls at baseline and their performance decreased 
pre- to post-clubbing in tasks measuring cognitive functioning, ii) cannabis and amphetamine use 
related to decreased cognitive performance in the pre-clubbing session, whereas mephedrone did 
not, iii) depression rather than drug use or schizotypy was the most consistent predictor of 
cognitive attenuations in the post-clubbing session, and iv) schizotypy did not explain variance in 
cognitive functioning (apart from CogDis in the pre-clubbing session) when controlling for drug 
use. These findings will be discussed in the following sections. 
 
We argued that the cognitive consequences of mephedrone use should mirror those of 
amphetamine use, because studies reported on physiological, chemical and psychological 
similarities between the consequences of amphetamine (such as ecstasy) and cathinone use (Dal 
Cason et al., 1997, Kalix, 1992, Schifano et al., 2010, ACMD, 2010, Vardakou et al., 2011, 
James et al., 2010, Morris, 2010, Brenneisen et al., 1990, Hoffman and Al'Absi, 2010, Wood and 
Dargan, 2012). For our pre-clubbing session, we observed that mephedrone users performed 
worse than the control group for immediate and delayed verbal recall, and verbal fluency. Our 
group results also showed that performance in all but the TMT task became worse over the pre-
clubbing to post-clubbing session in our mephedrone users as compared to controls. These group 
comparison results would suggest that recent mephedrone use negatively affects cognitive 
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functioning. We have, however, obtained more detailed information on other drug use as well, 
and this additional drug use was important to cognitive functioning.   
 
Firstly, we found that mephedrone users as compared to controls had consumed more 
amphetamines and nicotine in the 30 days prior to testing. Secondly, when looking at the 
individual contribution of drug use (regression analysis) on cognitive functioning, we found that 
enhanced cannabis and amphetamine use was related to memory impairments, whereas 
mephedrone use was not. These latter results are in line with studies on the cognitive effects of 
amphetamines (Hoshi et al., 2007, Morgan, 2000, see Gouzoulis-Mayfrank and Daumann, 2009, 
Rogers et al., 2009 for overview, Kuypers and Ramaekers, 2005), cathinones (Colzato et al., 
2011b), and cannabis (Fernández-Serrano et al., 2011) indicating impairments in verbal recall, 
verbal learning and/or fluency as a function of these drugs’ consumption. Our findings and the 
previous literature would thus suggest that mephedrone consumption does not necessarily exert a 
negative impact on cognitive functioning by itself. Instead, mephedrone users are likely those 
individuals who are prone to consuming other psychoactive drugs in conjunction with 
mephedrone. It might be this polydrug use that makes these individuals more vulnerable to the 
observed attenuations in the cognitive tasks. In line with this rationale, it seems difficult to find 
pure users of any one substance alone (Fernández-Serrano et al., 2011), and our sample has been 
no exception.  
 
The implication of polydrug use when trying to understand the influence of a particular drug on 
cognition is thus far-reaching. For instance, polydrug users may suffer exacerbated negative 
implications of drug use on mental health when compared to individual drug users (Bondi et al., 
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1998, Hakansson et al., 2011). Consequently, findings from psychopharmacological studies 
which pre-selected their participants according to drug naivety might not provide very 
representative results for a clinically relevant population. Moreover, when individual drug use is 
targeted (see Fernández-Serrano et al., 2011 for overview), we might neglect and miss out on the 
influence of other drugs frequently consumed simultaneously on the relationship we are 
interested in. Based on these considerations, we here conjecture that it is impossible to infer 
about the impact of a single drug on cognition in a research context using a sample of typical 
recreational drug users. Instead, we should take polydrug use more thoroughly into account, as 
former polydrug use might also influence cognitive functioning in substance users in the long-
term.  
 
Polydrug use and not only single drug use might be relevant for cognition and mood in the 
short-term, as was found here when considering post-clubbing performance and mood. In the 
regression analysis, we explored additional factors that could influence cognitive measures post-
clubbing more thoroughly. Strikingly, we found that higher BDI scores and prolonged sleep 
(rather than drug use or schizotypy) predicted a relative drop in cognitive performance. While 
not our a priori focus, the role of depression is worthwhile considering. To start with, our 
mephedrone users as compared to controls showed higher BDI scores both pre-clubbing and 
post-clubbing. Moreover, schizotypy scores showed no additional influence on cognitive 
functioning post-clubbing, and the influence of actual drug use seemed to become marginal when 
BDI scores were considered. We thus conjecture that depression might be a major confound in 
previous schizotypy and drug studies that targeted cognitive functions, because depression levels 
are commonly not assessed (e.g. Herzig et al., 2010, Skosnik et al., 2001). The same can be said 
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for studies testing non-clinical populations (and thus non-clinical depression) on the influence of 
particular drugs, where potentially relevant depression ratings have not been reported in 
relatively pure cannabis users (Fried et al., 2005), alcohol users (Ratti et al., 2002) or 
psychostimulant users (Bolla et al., 2003). Depression rates are, however, relatively elevated in 
e.g. amphetamine users (Morgan, 2000, Rogers et al., 2009 for overview), alcohol users (Wood 
and Dargan, 2012) and cannabis users (Hayatbakhsh et al., 2007, Patton et al., 2002). 
Consequently, if depression is a major confound in studies such as the present one, we would 
expect that depression influences cognitive functioning directly (primary influence) or indirectly 
(secondary influence through e.g. loss of motivation), much as we have originally expected this 
to be the case for drug use and / or schizotypy.  
 
Studies that tested the link between depression and cognitive functioning indeed report that 
clinical depression in young adults is accompanied by relatively impaired cognitive functioning 
including those we tested here (see Castaneda et al., 2008 for overview). Even in healthy 
subjects, negative mood can lead to reduced brain activity during verbal (not spatial) working 
memory tasks (Aoki et al., 2011). Finally, the mood-behavior model (Gendolla, 2000) predicts 
that negative mood results in disengagement and little resource mobilization when facing 
difficult tasks, as demands would be perceived as being too high (Silvestrini and Gendolla, 
2009). Given that negative mood is frequently a characteristic of depression, it is possible that 
task performance decreases the more individuals are depressed, due to decreased motivation 
(Locke and Braver, 2008, Engelmann et al., 2009).  
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Another possibility, though not necessarily independent of motivational factors, could be that the 
clubbing experience (including the drug consumption) resulted in neurochemical changes related 
to depression via serotonergic pathways, or more specifically through an attenuation of 
serotonergic functioning (Bhagwagar et al., 2006, Meyer et al., 2003, Meyer et al., 2004). 
Serotonin is a neurotransmitter, importantly linked to depression, to amphetamine use (see 
Walstab et al., 2010 for overview), and the interaction between depression and amphetamine use 
(see Darke et al., 2008 for overview, McCardle et al., 2004, Rogers et al., 2009, Morgan, 2000). 
In all cases, a reduction in serotonin availability seems to have negative consequences. For 
instance, taking amphetamines such as ecstasy is related to a drop in mood, observable about two 
days after its consumption (Curran and Travill, 1997, Parrott and Lasky, 1998), presumably via 
reductions in serotonin-receptor density and binding [McCann et al. (1998, 2008)]. These 
changes in serotonin functioning have also been related to verbal memory performance 
(Reneman et al., 2001). Interestingly, serotonin receptor functioning has been implicated in the 
rewarding effects of THC as well (Maldonado et al., 2011), and some studies suggest that the 
effect of amphetamine and cannabis on memory functions is accumulative when consumed in 
parallel (see Mohamed et al., 2011 for overview). Taken together, these findings suggest that 
amphetamine and cannabis use may have altered susceptibility to mood-related cognitive 
attenuations, either via motivational factors, neurochemical modulations, or both.  
 
To summarize, drug use was a consistent predictor of task performance in the long-term (pre-
clubbing), and may have induced mood-related attenuations in cognitive functioning in the short-
term (post-clubbing). Schizotypy, on the other hand, was largely irrelevant to cognitive 
functioning on top of (poly-)drug use. The only significant schizotypy finding was that enhanced 
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CogDis scores related to reduced verbal fluency. If we consider this single significant finding to 
be meaningful, the question arises whether some schizotypy dimensions are pathologically more 
relevant than others. Indeed, several researchers have indicated that CogDis is related to. 
unpleasant evaluation of unusual experiences (Schofield and Claridge, 2007), or cognitive 
attenuations and poor emotional processing (Kerns and Becker, 2008, Cappe et al., 2012). A 
problem is certainly the lack of consideration of disorganised symptoms in studies that found 
attenuated cognitive functioning relating to positive symptoms (Laws et al., 2011, Lenzenweger 
and Korfine, 1994), and that most of the psychometric tools used in these studies do not 
distinguish between the two symptom dimensions (Chapman et al., 1976, Eckblad and Chapman, 
1983, Chapman et al., 1978, Eysenck and Eysenck, 1975, Winterstein et al., 2011, Peters et al., 
1999).  
 
If cognitive disorganisation is considered to be a separate symptom dimension, it seems more 
relevant to cognitive performance than the positive symptom dimension. For instance, in a study 
by Rawlings and Goldberg (2012) performance in a continuous performance task was affected 
by higher cognitive disorganization, but not as consistently by other schizotypy dimensions. 
Similar conclusions on the role of symptom dimensions have also been drawn from studies in 
other schizotypal samples (Szöke et al., 2009, Chan et al., 2011, Colzato et al., 2011a, Cappe et 
al., 2012) and in schizophrenia patients (Kebir et al., 2008, Lucas et al., 2004). With regard to 
schizotypy, positive symptoms have even been associated with performance benefits such as in 
creativity tasks (Nelson and Rawlings, 2010, Mohr et al., 2001, Batey and Furnham, 2008). It 
might be the case that scoring high on positive schizotypy only relates to a well-adapted 
cognitive profile, while high scores in CogDis alone or in combination with high scores in 
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positive schizotypy might yield the most disadvantageous cognitive profile (Schofield and 
Claridge, 2007, Cappe et al., 2012). Our results would support this notion.  
 
Study limitations and implications 
Our study population consisted of volunteers who were willing to come to the laboratory twice, 
shortly before and after a clubbing night. Moreover, testing had to be completed within two 
months. These study constraints reduced the number of possible participants, and by inference 
the overall sample size. Given our naturalistic designs, we nevertheless argue that our results are 
informative (Fernández-Serrano et al., 2011), and stress that we could retain a considerable 
number of participants despite their clubbing activity, and decreased mood. These volunteers 
committed themselves to be tested twice around their clubbing experience, turning this sample 
and the measurements into a valuable data pool. Only with this naturalistic design were we able 
to assess the long-term (pre-clubbing) and short-term (post-clubbing) effects of drug use as it 
might occur in everyday situations. We  suggest that the current study, its design and results 
revealed important new findings that should be followed up in future studies, including 
laboratory ones (the role of depression, mediation of results by the emotional consequences of 
the clubbing / drug experience not observable in laboratory tests of drug exposure, the problem 
of poly-drug use).  
 
Illicit drug use and depression are associated, but so are licit drugs. For instance, alcohol 
negatively influences mood, and the accumulation of this effect could be related to the 
depression rate increase seen in mephedrone users as well. According to recent meta-analyses, 
alcohol increases the risk for depression (Boden and Fergusson, 2011), is related to impairments 
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in memory and verbal fluency (see Fernández-Serrano et al., 2011 for overview, Zeigler et al., 
2005, Manning et al., 2008, Wendt and Risberg, 2001), and hangovers are usually associated 
with low mood (Howland et al., 2010). Moreover, alcohol seems to affect serotonin-receptor 
functioning, similarly to amphetamines (McHugh et al., 2010, Vengeliene et al., 2008). Given 
that alcohol has been used more frequently between test sessions in mephedrone users, we 
assume important interaction effects with alcohol.  
 
It is also possible that the effects of mephedrone become more pronounced in chronic users, or 
those that use the drug at a high frequency, as in our sample use was relatively low (about 1.5 
times/month). Another possibility is that unreported (intentionally taken) or unknown (e.g. 
participants consumed impure mephedrone) substances were taken, influencing cognitive 
performance. We did not confirm individuals’ self-report with objective drug tests.  
However, we here suggest that the likelihood is high that participants actually consumed 
mephedrone when assuming to do so. The current study was completed within five months 
shortly after the ban for mephedrone had been implemented in the UK and other 
European countries (see Vardakou et al., 2011 for overview, Winstock et al., 2011, 
EMCDDA, 2010a, EMCDDA, 2011, EMCDDA, 2012). Very likely, participants consumed 
mephedrone that had been widely available and bought online before the implementation 
of the ban (EMCDDA, 2011, EMCDDA, 2012). Even though there is a debate about the 
quality of mephedrone purchased from internet portals (Davies et al., 2010), many reports 
would agree on its high purity (Gibbons and Zloh, 2010, EMCDDA, 2010b). Consequently, 
we assume that our participants actually consumed mephedrone of relatively high purity.  
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Furthermore, it could have been advantageous to test the effects of mephedrone use in a sample 
of less educated subjects. IQ may have the potential to protect from adverse situations in e.g. 
psychiatric illnesses (MacCabe and Murray, 2004, Moore et al., 2007, Sørensen et al., 2010) or 
substance use (Pope et al., 2003, Zammit et al., 2010). However, in our sample most participants 
were students, or educated to at least degree level. Therefore, more variance in subjects’ 
educational level/IQ could be informative in subsequent studies. 
 
Conclusion 
We set out to investigate the effects of mephedrone use on cognition, and elucidate the 
relationship between drug use, schizotypal symptoms and cognitive functioning. Results showed 
that even before clubbing (and after recent drug use) mephedrone users performed worse than 
non-users on cognitive tasks. In mephedrone users but not in controls, performance in verbal 
learning and fluency decreased over the clubbing experience. Additional analysis on the use of 
other drugs and psychological factors, however, indicated that the changes in cognitive 
functioning were likely due to prior polydrug use (amphetamine, cannabis and alcohol use in 
particular), and related psychological consequences (enhanced depression rates). Schizotypal 
traits were rather unrelated to cognitive performance, apart from CogDis. This schizotypy 
subscale may therefore represent a pathologically more relevant symptom dimension. The 
present study shows that polydrug use should be considered in future studies on drug effects on 
cognition, as well as relevant associated psychological concepts (depression, schizotypy). Given 
the political interest in preventing the population from harmful drug effects, knowing which 
conditions increase risk is warranted, particularly because a more regulated drug policy has been 
called for from various professional domains (Nutt et al., 2010, Bennett and Holloway, 2010).  
Page 27 of 45
http://mc.manuscriptcentral.com/hup
Human Psychopharmacology: Clinical and Experimental
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 28 
Acknowledgements 
We would like to thank Birgit Whitman for aid with ethical issues, and Prof. David Nutt for his 
valuable advice.
Page 28 of 45
http://mc.manuscriptcentral.com/hup
Human Psychopharmacology: Clinical and Experimental
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 29 
References 
ACMD 2010. Advisory Council on the Misuse of Drugs. Consideration of the cathinones. 
Aoki, R., Sato, H., Katura, T., Utsugi, K., Koizumi, H., Matsuda, R. & Maki, A. 2011. 
Relationship of negative mood with prefrontal cortex activity during working memory 
tasks: An optical topography study. Neuroscience Research, 70, 189-196. 
Army Individual Test Battery 1944. Manual of Directions and Scoring, Washington, DC: War 
Department, Adjutant General’s Office. 
Badcock, J. C., Dragović, M., Dawson, L. & Jones, R. 2011. Normative Data for Rey's Auditory 
Verbal Learning Test in Individuals with Schizophrenia. Archives of Clinical 
Neuropsychology. 
Barkus, E. & Murray, R. M. 2010. Substance Use in Adolescence and Psychosis: Clarifying the 
Relationship. Annual Review of Clinical Psychology, 6, 365-389. 
Batey, M. & Furnham, A. 2008. The relationship between measures of creativity and schizotypy. 
Personality and Individual Differences, 45, 816-821. 
Bechtoldt, H. P., Fogel, M. L. & Benton, A. L. 1962. An application of factor-analysis in 
neuropsychology. Psychological Record, 12, 147-&. 
Beck, A. T., Erbaugh, J., Ward, C. H., Mock, J. & Mendelsohn, M. 1961. An Inventory for 
Measuring Depression. Archives of General Psychiatry, 4, 561-&. 
Bennett, T. & Holloway, K. 2010. Is UK drug policy evidence based? International Journal of 
Drug Policy, 21, 411-417. 
Bhagwagar, Z., Hinz, R., Taylor, M., Fancy, S., Cowen, P. & Grasby, P. 2006. Increased 5-
HT2A Receptor Binding in Euthymic, Medication-Free Patients Recovered From 
Depression: A Positron Emission Study With [11C]MDL 100,907. American Journal of 
Psychiatry, 163, 1580-1587. 
Bird, V., Premkumar, P., Kendall, T., Whittington, C., Mitchell, J. & Kuipers, E. 2010. Early 
intervention services, cognitive-behavioural therapy and family intervention in early 
psychosis: systematic review. The British Journal of Psychiatry, 197, 350-356. 
Blanchard, M. M., Jacobson, S., Clarke, M. C., Connor, D., Kelleher, I., Garavan, H., Harley, M. 
& Cannon, M. 2010. Language, motor and speed of processing deficits in adolescents 
with subclinical psychotic symptoms. Schizophrenia R search, 123, 71-76. 
Boden, J. M. & Fergusson, D. M. 2011. Alcohol and depression. Addiction, 106, 906-914. 
Bolla, K. I., Eldreth, D. A., London, E. D., Kiehl, K. A., Mouratidis, M., Contoreggi, C., 
Matochik, J. A., Kurian, V., Cadet, J. L., Kimes, A. S., Funderburk, F. R. & Ernst, M. 
2003. Orbitofrontal cortex dysfunction in abstinent cocaine abusers performing a 
decision-making task. NeuroImage, 19, 1085-1094. 
Bondi, M. W., Drake, A. I. & Grant, I. 1998. Verbal learning and memory in alcohol abusers and 
polysubstance abusers with concurrent alcohol abuse. Journal of the International 
Neuropsychological Society, 4, 319-328. 
Brenneisen, R., Fisch, H. U., Koelbing, U., Geisshusler, S. & Kalix, P. 1990. Amphetamine-like 
effects in humans of the khat alkaloid cathinone. British Journal of Clinical 
Pharmacology, 30, 825-828. 
Burch, G. S., Hemsley, D. R., Corr, P. J. & Gwyer, P. 2006. The relationship between incidental 
learning and multi-dimensional schizotypy as measured by the Oxford-Liverpool 
Inventory of Feelings and Experiences (O-LIFE). Personality and Individual Differences, 
40, 385-394. 
Page 29 of 45
http://mc.manuscriptcentral.com/hup
Human Psychopharmacology: Clinical and Experimental
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 30 
Burch, G. S., Hemsley, D. R. & Joseph, M. H. 2004. Trials-to-criterion latent inhibition in 
humans as a function of stimulus pre-exposure and positive-schizotypy. British Journal 
of Psychology, 95, 179-96. 
Cappe, C., Herzog, M. H., Herzig, D. A., Brand, A. & Mohr, C. 2012. Cognitive disorganisation 
in schizotypy is associated with deterioration in visual backward masking. Psychiatry 
Research, 200, 652-659. 
Carhart-Harris, R. L., Nutt, D. J., Munafo, M. & Wilson, S. J. 2008. Current and former ecstasy 
users report different sleep to matched controls: a web-based questionnaire study. Journal 
of Psychopharmacology, 23, 249-257. 
Castaneda, A. E., Tuulio-Henriksson, A., Marttunen, M., Suvisaari, J. & Lönnqvist, J. 2008. A 
review on cognitive impairments in depressive and anxiety disorders with a focus on 
young adults. Journal of Affective Disorders, 106, 1-27. 
Chan, R. C. K., Wang, Y., Yan, C., Song, L.-L., Wang, Y.-N., Shi, Y.-F., Gong, Q.-Y. & 
Cheung, E. F. C. 2011. Contribution of specific cognitive dysfunction to people with 
schizotypal personality. Psychiatry Research, 186, 71-75. 
Chapman, L. J., Chapman, J. P., Kwapil, T. R., Eckblad, M. & Zinser, M. C. 1994. Putatively 
psychosis-prone subjects 10 years later. Journal of Abnormal Psychology, 103, 171-183. 
Chapman, L. J., Chapman, J. P. & Raulin, M. L. 1976. Scales for physical and social anhedonia. 
Journal of Abnormal Psychology, 85, 374-382. 
Chapman, L. J., Chapman, J. P. & Raulin, M. L. 1978. Body-image aberration in schizophrenia. 
Journal of Abnormal Psychology, 87, 399 - 407. 
Colzato, L. S., Ruiz, M., Van Den Wildenberg, W. P. M., Bajo, M. T. & Hommel, B. 2011a. 
Long-term Effects of Chronic Khat Use: Impaired Inhibitory Control. Frontiers in 
Psychology, 1. 
Colzato, L. S., Ruiz, M. J., Van Den Wildenberg, W. P. M. & Hommel, B. 2011b. Khat Use Is 
Associated with Impaired Working Memory and Cognitive Flexibility. PLoS ONE, 6, 
e20602. 
Colzato, L. S., Ruiz, M. J., Van Den Wildenberg, W. P. M. & Hommel, B. 2012. Khat use is 
associated with increased response conflict in humans. Human Psychopharmacology: 
Clinical and Experimental, 27, 315-321. 
Crawford, J. R., Parker, D. M., Stewart, L. E., Besson, J. a. O. & Delacey, G. 1989. Prediction of 
the WAIS IQ with the National Adult Reading Test - Cross validation and extension. 
British Journal of Clinical Psychology, 28, 267-273. 
Crews, F. T. & Boettiger, C. A. 2009. Impulsivity, frontal lobes and risk for addiction. 
Impulsivity and Frontal Lobes: Roles in Psychopathology and Addiction, 93, 237-247. 
Curran, H. V. & Travill, R. A. 1997. Mood and cognitive effects of ± 3,4-
methylenedioxymethamphetamine (MDMA, ‘ecstasy’): week-end ‘high’ followed by 
mid-week low. Addiction, 92, 821-831. 
Dal Cason, T. A., Young, R. & Glennon, R. A. 1997. Cathinone: An Investigation of Several N-
Alkyl and Methylenedioxy-Substituted Analogs. Pharmacology Biochemistry and 
Behavior, 58, 1109-1116. 
Daneluzzo, E., Bustini, M., Stratta, P., Casacchia, M. & Rossi, A. 1998. Schizotypal personality 
questionnaire and wisconsin card sorting test in a population of DSM-III-R schizophrenic 
patients and control subjects. Comprehensive Psychiatry, 39, 143-148. 
Page 30 of 45
http://mc.manuscriptcentral.com/hup
Human Psychopharmacology: Clinical and Experimental
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 31 
Dargan, P. I., Albert, S. & Wood, D. M. 2010. Mephedrone use and associated adverse effects in 
school and college/university students before the UK legislation change. Quarterly 
Journal Of Medicine, 103, 875-879. 
Darke, S., Kaye, S., Mcketin, R. & Duflou, J. 2008. Major physical and psychological harms of 
methamphetamine use. Drug and Alcohol Review, 27, 253-262. 
Davies, S., Wood, D. M., Smith, G., Button, J., Ramsey, J., Archer, R., Holt, D. W. & Dargan, P. 
I. 2010. Purchasing ‘legal highs’ on the Internet—is there consistency in what you get? 
QJM, 103, 489-493. 
Davison, D. & Parrott, A. C. 1997. Ecstasy (MDMA) in Recreational Users: Self-Reported 
Psychological and Physiological Effects. Human Psychopharmacology: Clinical and 
Experimental, 12, 221-226. 
Deykin, E. Y., Levy, J. C. & Wells, V. 1987. Adolescent depression, alcohol and drug abuse. 
American Journal of Public Health, 77, 178-182. 
Diforio, D., Walker, E. F. & Kestler, L. P. 2000. Executive functions in adolescents with 
schizotypal personality disorder. Schizophrenia Research, 42, 125-134. 
Dinn, W. M., Harris, C. L., Aycicegi, A., Greene, P. & Andover, M. S. 2002. Positive and 
negative schizotypy in a student sample: neurocognitive and clinical correlates. 
Schizophrenia Research, 56, 171-185. 
Eckblad, M. & Chapman, L. J. 1983. Magical ideation as an indicator of schizotypy. Journal of 
consulting and clinical psychology, 51, 215-25. 
EMCDDA 2010a. The state of the drugs problem in Europe. Annual Report 2010 
(http://www.emcdda.europa.eu/events/2010/annual-report). 
EMCDDA 2010b. Synthetic cathinones (http://www.emcdda.europa.eu/publications/drug-
profiles/synthetic-cathinones). 
EMCDDA 2011. A follow-up on mephedrone. Annual Report 2011 
(http://www.emcdda.europa.eu/online/annual-report/2011/new-drugs-and-trends/3). 
EMCDDA 2012. Annual report on the state of the drugs problem in Europe 
(http://www.emcdda.europa.eu/publications/annual-report/2012). 
Engelmann, J. B., Damaraju, E., Padmala, S. & Pessoa, L. 2009. Combined effects of attention 
and motivation on visual task performance: transient and sustained motivational effects. 
Frontiers in Human Neuroscience, 3. 
Eysenck, H. J. & Eysenck, S. B. G. 1975. Manual of the Eysenck Personality Questionnaire 
(Junior and Adult), Kent, UK, Hodder & Stoughton. 
Fernandez-Serrano, M. J., Perez-Garcia, M., Rio-Valle, J. S. & Verdejo-Garcia, A. 2010. 
Neuropsychological consequences of alcohol and drug abuse on different components of 
executive functions. Journal of Psychopharmacology, 24, 1317-1332. 
Fernández-Serrano, M. J., Pérez-García, M. & Verdejo-García, A. 2011. What are the specific 
vs. generalized effects of drugs of abuse on neuropsychological performance? 
Neuroscience & Biobehavioral Reviews, 35, 377-406. 
Fridberg, D. J., Vollmer, J. M., O'donnell, B. F. & Skosnik, P. D. 2011. Cannabis users differ 
from non-users on measures of personality and schizotypy. Psychiatry Research, 186, 46-
52. 
Fried, P. A., Watkinson, B. & Gray, R. 2005. Neurocognitive consequences of marihuana--a 
comparison with pre-drug performance. Neurotoxicology and Teratology, 27, 231-239. 
Gendolla, G. H. E. 2000. On the Impact of Mood on Behavior: An Integrative Theory and a 
Review. Review of General Psychology, 4, 378-408. 
Page 31 of 45
http://mc.manuscriptcentral.com/hup
Human Psychopharmacology: Clinical and Experimental
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 32 
Gibbons, S. & Zloh, M. 2010. An analysis of the ‘legal high’ mephedrone. Bioorganic & 
Medicinal Chemistry Letters, 20, 4135-4139. 
Giraldez, S. L., Caro, M. I., Rodrigo, A. M. L., Pineiro, M. P. & Gonzalez, J. L. B. 1999. 
Assessment of essential components of schizotypy by means of neurocognitive measures. 
Psicothema, 11, 477-494. 
Gonzalez, R., Rippeth, J. D., Carey, C. L., Heaton, R. K., Moore, D. J., Schweinsburg, B. C., 
Cherner, M. & Grant, I. 2004. Neurocognitive performance of methamphetamine users 
discordant for history of marijuana exposure. Drug and Alcohol Dependence, 76, 181-
190. 
Gooding, D. C., Tallent, K. A. & Matts, C. W. 2005. Clinical status of at-risk individuals 5 years 
later: Further validation of the psychometric high-risk strategy. Journal of Abnormal 
Psychology, 114, 170-175. 
Gouzoulis-Mayfrank, E. & Daumann, J. 2009. Neurotoxicity of drugs of abuse--the case of 
methylenedioxyamphetamines (MDMA, ecstasy), and amphetamines. Dialogues in 
Clinical Neuroscience, 11, 305-17. 
Hakansson, A., Schlyter, F. & Berglund, M. 2011. Associations between polysubstance use and 
psychiatric problems in a criminal justice population in Sweden. Drug and Alcohol 
Dependence, 118, 5-11. 
Hanson, K. L. & Luciana, M. 2004. Neurocognitive function in users of MDMA: the importance 
of clinically significant patterns of use. Psychological Medicine, 34, 229-246. 
Hayatbakhsh, M. R., Najman, J. M., Jamrozik, K., Mamun, A. A., Alati, R. & Bor, W. 2007. 
Cannabis and Anxiety and Depression in Young Adults: A Large Prospective Study. 
Journal of the American Academy of Child & Adolescent Psychiatry, 46, 408-417. 
Herzig, D. A. & Mohr, C. 2012. Stressing schizotypy: The modulating role of stress-relieving 
behaviours and intellectual capacity on functional hemispheric asymmetry. Laterality: 
Asymmetries of Body, Brain and Cognition, 1-27. 
Herzig, D. A., Tracy, J., Munafò, M. & Mohr, C. 2010. The influence of tobacco consumption on 
the relationship between schizotypy and hemispheric asymmetry. Journal of Behavior 
Therapy and Experimental Psychiatry, 41, 397-408. 
Hoffman, R. & Al'absi, M. 2010. Khat use and neurobehavioral functions: Suggestions for future 
studies. Journal of Ethnopharmacology, 132, 554-563. 
Hoshi, R., Mullins, K., Boundy, C., Brignell, C., Piccini, P. & Curran, H. 2007. Neurocognitive 
function in current and ex-users of ecstasy in comparison to both matched polydrug-using 
controls and drug-naïve controls. Psychopharmacology, 194, 371-379. 
Howland, J., Rohsenow, D. J., Greece, J. A., Littlefield, C. A., Almeida, A., Heeren, T., Winter, 
M., Bliss, C. A., Hunt, S. & Hermos, J. 2010. The effects of binge drinking on college 
students' next-day academic test-taking performance and mood state. Addiction, 105, 
655-665. 
James, D., Adams, R. D., Spears, R., Cooper, G., Lupton, D. J., Thompson, J. P. & Thomas, S. 
H. L. 2010. Clinical characteristics of mephedrone toxicity reported to the UK National 
Poisons Information Service. Emergency Medicine Journal. 
Kaczorowski, J. A., Barrantes-Vidal, N. & Kwapil, T. R. 2009. Neurological soft signs in 
psychometrically identified schizotypy. Schizophrenia Research, 115, 293-302. 
Kalechstein, A., De La Garza, R., Mahoney, J., Fantegrossi, W. & Newton, T. 2007. MDMA use 
and neurocognition: a meta-analytic review. Psychopharmacology, 189, 531-537. 
Kalix, P. 1992. Cathinone, a Natural Amphetamine. Pharmacology & Toxicology, 70, 77-86. 
Page 32 of 45
http://mc.manuscriptcentral.com/hup
Human Psychopharmacology: Clinical and Experimental
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 33 
Kebir, O., Dellagi, L., Ben Azouz, O., Rabeh, Y., Sidhom, O. & Tabbane, K. 2008. Déficits des 
fonctions exécutives dans la schizophrénie selon les dimensions positive, négative et de 
désorganisation. Annales Médico-psychologiques, revue psychiatrique, 166, 627-632. 
Kerns, J. G. & Becker, T. M. 2008. Communication disturbances, working memory, and emotion 
in people with elevated disorganized schizotypy. Schizophrenia Research, 100, 172-180. 
Kim, M.-S., Oh, S. H., Hong, M.-H. & Choi, D. B. 2011. Neuropsychologic profile of college 
students with schizotypal traits. Comprehensive Psychiatry, 52, 511-516. 
King, G., Alicata, D., Cloak, C. & Chang, L. 2010. Neuropsychological deficits in adolescent 
methamphetamine abusers. Psychopharmacology, 212, 243-249. 
Kopp, B., Wolff, M., Hruska, C. & Reischies, F. M. 2002. Brain mechanisms of visual encoding 
and working memory in psychometrically identified schizotypal individuals and after 
acute administration of haloperidol. Psychophysiology, 39, 459-472. 
Koychev, I., Mcmullen, K., Lees, J., Dadhiwala, R., Grayson, L., Perry, C., Schmechtig, A., 
Walters, J., Craig, K. J., Dawson, G. R., Dourish, C. T., Ettinger, U., Wilkinson, L., 
Williams, S., Deakin, J. F. W. & Barkus, E. 2011. A validation of cognitive biomarkers 
for the early identification of cognitive enhancing agents in schizotypy: A three-center 
double-blind placebo-controlled study. European Neuropsychopharmacology : The 
Journal of the European College of Neuropsychopharmacology. 
Krabbendam, L., Myin-Germeys, I., Hanssen, M. & Van Os, J. 2005. Familial covariation of the 
subclinical psychosis phenotype and verbal fluency in the general population. 
Schizophrenia Research, 74, 37-41. 
Kuypers, K. P. C. & Ramaekers, J. G. 2005. Transient memory impairment after acute dose of 
75mg 3.4-Methylene-dioxymethamphetamine. Journal of Psychopharmacology, 19, 633-
639. 
Larsen, T. K., Melle, I., Auestad, B., Haahr, U., Joa, I., Johannessen, J. O., Opjordsmoen, S., 
Rund, B. R., Rossberg, J. I., Simonsen, E., Vaglum, P., Friis, S. & Mcglashan, T. 2011. 
Early detection of psychosis: positive effects on 5-year outcome. Psychological medicine, 
41, 1461-1469. 
Laurent, A., Biloa-Tang, M., Bougerol, T., Duly, D., Anchisi, A.-M., Bosson, J.-L., Pellat, J., 
D'amato, T. & Dalery, J. 2000. Executive/attentional performance and measures of 
schizotypy in patients with schizophrenia and in their nonpsychotic first-degree relatives. 
Schizophrenia Research, 46, 269-283. 
Laurent, A., Halim, V., Sechier, P., Daumal, M., Foussard, N., Dumas, P., Dalery, J. & D'amato, 
T. 2001. Vulnerability to schizophrenia: neuropsychological performances and 
schizotypal features. Encephale-Revue De Psychiatrie Clinique Biologique Et 
Therapeutique, 27, 173-179. 
Laws, K. R. & Kokkalis, J. 2007. Ecstasy (MDMA) and memory function: a meta-analytic 
update. Human Psychopharmacology: Clinical and Experimental, 22, 381-388. 
Laws, K. R., Kondel, T. K., Clarke, R. & Nillo, A.-M. 2011. Delusion-prone individuals: Stuck 
in their ways? Psychiatry Research, 186, 219-224. 
Lenzenweger, M. F. & Korfine, L. 1994. Perceptual Aberrations, Schizotypy, and the Wisconsin 
Card Sorting Test. Schizophrenia Bulletin, 20, 345-357. 
Lezak, M. D. 1995. Neuropsychological assessment (3rd ed.), Oxford, NY  
Locke, H. & Braver, T. 2008. Motivational influences on cognitive control: Behavior, brain 
activation, and individual differences. Cognitive, Affective, & Behavioral Neuroscience, 
8, 99-112. 
Page 33 of 45
http://mc.manuscriptcentral.com/hup
Human Psychopharmacology: Clinical and Experimental
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 34 
Lucas, S., Fitzgerald, D., Redoblado-Hodge, M. A., Anderson, J., Sanbrook, M., Harris, A. & 
Brennan, J. 2004. Neuropsychological correlates of symptom profiles in first episode 
schizophrenia. Schizophrenia Research, 71, 323-330. 
MacCabe, J. H. & Murray, R. M. 2004. Intellectual functioning in schizophrenia: a marker of 
neurodevelopmental damage? Journal of Intellectual Disability Research, 48, 519-523. 
MacInnes, N., Handley, S. L. & Harding, G. F. A. 2001. Former chronic 
methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive 
symptoms. Journal of Psychopharmacology, 15, 181-186. 
Maldonado, R., Berrendero, F., Ozaita, A. & Robledo, P. 2011. Neurochemical basis of cannabis 
addiction. Neuroscience, 181, 1-17. 
Manning, V., Wanigaratne, S., Best, D., Hill, R. G., Reed, L. J., Ball, D., Marshall, J., Gossop, 
M. & Strang, J. 2008. Changes in Neuropsychological Functioning during Alcohol 
Detoxification. European Addiction Research, 14, 226-233. 
Marshall, M. & Rathbone, J. 2006. Early intervention for psychosis. Cochrane Database of 
Systematic Reviews. 
Mason, O., Claridge, G. & Jackson, M. 1995. New Scales for the Assessment of Schizotypy. 
Personality and Individual Differences, 18, 7-13. 
Mason, O., Linney, Y. & Claridge, G. 2005. Short scales for measuring schizotypy. 
Schizophrenia Research, 78, 293-296. 
Matheson, S. & Langdon, R. 2008. Schizotypal traits impact upon executive working memory 
and aspects of IQ. Psychiatry Research, 159, 207-214. 
McCann, U., Szabo, Z., Vranesic, M., Palermo, M., Mathews, W., Ravert, H., Dannals, R. & 
Ricaurte, G. 2008. Positron emission tomographic studies of brain dopamine and 
serotonin transporters in abstinent (±)3,4-methylenedioxymethamphetamine (“ecstasy”) 
users: relationship to cognitive performance. Psychopharmacology, 200, 439-450. 
McCann, U. D., Szabo, Z., Scheffel, U., Dannals, R. F. & Ricaurte, G. A. 1998. Positron 
emission tomographic evidence of toxic effect of MDMA (?Ecstasy?) on brain serotonin 
neurons in human beings. The Lancet, 352, 1433-1437. 
McCardle, K., Luebbers, S., Carter, J. D., Croft, R. J. & Stough, C. 2004. Chronic MDMA 
(ecstasy) use, cognition and mood. Psychopharmacology, 173, 434-439. 
McHugh, R. K., Hofmann, S. G., Asnaani, A., Sawyer, A. T. & Otto, M. W. 2010. The serotonin 
transporter gene and risk for alcohol dependence: A meta-analytic review. Drug and 
Alcohol Dependence, 108, 1-6. 
Meehl, P. E. 1962. Schizotaxia, Schizotypy, Schizophrenia. American Psychologist, 17, 827-838. 
Menard, S. 1995. Applied logistic regression analysis., Thousand Oaks, CA. 
Meyer, J. H., Houle, S., Sagrati, S., Carella, A., Hussey, D. F., Ginovart, N., Goulding, V., 
Kennedy, J. & Wilson, A. A. 2004. Brain Serotonin Transporter Binding Potential 
Measured With Carbon 11-Labeled DASB Positron Emission Tomography: Effects of 
Major Depressive Episodes and Severity of Dysfunctional Attitudes. Archives of General 
Psychiatry, 61, 1271-1279. 
Meyer, J. H., Mcmain, S., Kennedy, S. H., Korman, L., Brown, G. M., Dasilva, J. N., Wilson, A. 
A., Blak, T., Eynan-Harvey, R., Goulding, V. S., Houle, S. & Links, P. 2003. 
Dysfunctional Attitudes and 5-HT2 Receptors During Depression and Self-Harm. 
American Journal of Psychiatry, 160, 90-99. 
Page 34 of 45
http://mc.manuscriptcentral.com/hup
Human Psychopharmacology: Clinical and Experimental
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 35 
Mohamed, W. M. Y., Hamida, S. B., Cassel, J.-C., De Vasconcelos, A. P. & Jones, B. C. 2011. 
MDMA: Interactions with other psychoactive drugs. Pharmacology Biochemistry and 
Behavior, 99, 759-774. 
Mohr, C., Graves, R. E., Gianotti, L. R. R., Pizzagalli, D. & Brugger, P. 2001. Loose but 
Normal: A Semantic Association Study. Journal of Psycholinguistic Research, 30, 475-
483. 
Moore, T. H. M., Zammit, S., Lingford-Hughes, A., Barnes, T. R. E., Jones, P. B., Burke, M. & 
Lewis, G. 2007. Cannabis use and risk of psychotic or affective mental health outcomes: 
a systematic review. Lancet, 370, 319-328. 
Morgan, M. J. 2000. Ecstasy (MDMA): a review of its possible persistent psychological effects. 
Psychopharmacology, 152, 230-248. 
Morris, K. 2010. UK places generic ban on mephedrone drug family. The Lancet, 375, 1333-
1334. 
Nelson, B. & Rawlings, D. 2010. Relating Schizotypy and Personality to the Phenomenology of 
Creativity. Schizophrenia Bulletin, 36, 388-399. 
Nelson, H. E. 1982. National Adult Reading Test (NART) Test Manual, Berkshire, Nfer-Nelson. 
Newman, L. M., Trivedi, M. A., Bendlin, B. B., Ries, M. L. & Johnson, S. C. 2007. The 
Relationship Between Gray Matter Morphometry and Neuropsychological Performance 
in a Large Sample of Cognitively Healthy Adults. Brain Imaging and Behavior, 1, 3-10. 
Nutt, D. J., King, L. A. & Phillips, L. D. 2010. Drug harms in the UK: a multicriteria decision 
analysis. The Lancet, 376, 1558-1565. 
Park, S., Holzman, P. S. & Lenzenweger, M. F. 1995. Individual Differences in Spatial Working 
Memory in Relation to Schizotypy. Journal of Abnormal Psychology, 104, 355-363. 
Park, S. & Mctigue, K. 1997. Working memory and the syndromes of schizotypal personality. 
Schizophrenia Research, 26, 213-220. 
Parrott, A. C. & Lasky, J. 1998. Ecstasy (MDMA) effects upon mood and cognition: before, 
during and after a Saturday night dance. Psychopharmacology, 139, 261-268. 
Patton, G. C., Coffey, C., Carlin, J. B., Degenhardt, L., Lynskey, M. & Hall, W. 2002. Cannabis 
use and mental health in young people: cohort study. British Medical Journal, 325, 1195-
1198. 
Peters, E. R., Joseph, S. A. & Garety, P. A. 1999. Measurement of Delusional Ideation in the 
Normal Population: Introducing the PDI (Peters et al. Delusions Inventory). 
Schizophrenia Bulletin, 25, 553-576. 
Pope, H. G., Gruber, A. J., Hudson, J. I., Cohane, G., Huestis, M. A. & Yurgelun-Todd, D. 2003. 
Early-onset cannabis use and cognitive deficits: what is the nature of the association? 
Drug and Alcohol Dependence, 69, 303-310. 
Poreh, A. M., Ross, T. P. & Whitman, R. D. 1995. Reexamination of executive functions in 
psychosis-prone college students. Personality and Individual Differences, 18, 535-539. 
Prosser, J. & Nelson, L. 2012. The Toxicology of Bath Salts: A Review of Synthetic Cathinones. 
Journal of Medical Toxicology, 8, 33-42. 
Ratti, M. T., Bo, P., Giardini, A. & Soragna, D. 2002. Chronic alcoholism and the frontal lobe: 
which executive functions are imparied? Acta Neurologica Scandinavica, 105, 276-281. 
Reichenberg, A. & Harvey, P. D. 2007. Neuropsychological impairments in schizophrenia: 
Integration of performance-based and brain imaging findings. Psychological Bulletin, 
133, 833-858. 
Page 35 of 45
http://mc.manuscriptcentral.com/hup
Human Psychopharmacology: Clinical and Experimental
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 36 
Reitan, R. M. & Wolfson, D. 1985. The Halstead–Reitan Neuropsycholgical Test Battery: 
Therapy and clinical interpretation., Tucson, AZ, Neuropsychological Press. 
Reneman, L., Lavalaye, J., Schmand, B., De Wolff, F. A., Van Den Brink, W., Den Heeten, G. J. 
& Booij, J. 2001. Cortical Serotonin Transporter Density and Verbal Memory in 
Individuals Who Stopped Using 3,4-Methylenedioxymethamphetamine (MDMA or 
"Ecstasy"): Preliminary Findings. Archives of General Psychiatry, 58, 901-906. 
Rogers, G., Elston, J., Garside, R., Roome, C., Taylor, R., Younger, P., Zawada, A. & 
Somerville, M. 2009. The harmful health effects of recreational ecstasy: a systematic 
review of observational evidence. Health Technology Assessment, 13, 1-+. 
Ruff, R. M., Light, R. H., Parker, S. B. & Levin, H. S. 1996. Benton controlled oral word 
association test: Reliability and updated norms. Archives of Clinical Neuropsychology, 
11, 329-338. 
Schifano, F., Albanese, A., Fergus, S., Stair, J., Deluca, P., Corazza, O., Davey, Z., Corkery, J., 
Siemann, H., Scherbaum, N., Farre’, M., Torrens, M., Demetrovics, Z. & Ghodse, A. 
2010. Mephedrone (4-methylmethcathinone; ‘meow meow’): chemical, pharmacological 
and clinical issues. Psychopharmacology, 1-10. 
Schofield, K. L. & Claridge, G. 2007. Paranormal experiences and mental health: Schizotypy as 
an underlying factor. Personality and Individual Differences, 43, 1908-1916. 
Silvestrini, N. & Gendolla, G. H. E. 2009. The joint effect of mood, task valence, and task 
difficulty on effort-related cardiovascular response and facial EMG. International 
Journal of Psychophysiology, 73, 226-234. 
Skosnik, P. D., Spatz-Glenn, L. & Park, S. 2001. Cannabis use is associated with schizotypy and 
attentional disinhibition. Schizophrenia Research, 48, 83-92. 
Sørensen, H. J., Mortensen, E. L., Schiffman, J., Ekstrøm, M., Denenney, D. & Mednick, S. A. 
2010. Premorbid IQ and adult schizophrenia spectrum disorder: Verbal Performance 
subtests. Psychiatry Research, 178, 23-26. 
Sotiropoulos, A., Papazafiropoulou, A., Apostolou, O., Kokolaki, A., Gikas, A. & Pappas, S. 
2008. Prevalence of depressive symptoms among non insulin treated Greek type 2 
diabetic subjects. BioMed Central Research Notes, 1, 101. 
Spreen, O. & Strauss, E. 1998. A compendium of neuropsychological tests: administration, 
norms and commentary, New York, Oxford University Press. 
Suhr, J. A. 1997. Executive functioning deficits in hypothetically psychosis-prone. 
Schizophrenia Research, 27, 29-35. 
Szöke, A., Méary, A., Ferchiou, A., Trandafir, A., Leboyer, M. & Schürhoff, F. 2009. 
Correlations between cognitive performances and psychotic or schizotypal dimensions. 
European Psychiatry, 24, 244-250. 
Tombaugh, T. N. 2004. Trail Making Test A and B: Normative data stratified by age and 
education. Archives of Clinical Neuropsychology, 19, 203-214. 
Tsakanikos, E. & Claridge, G. 2005. More words, less words: Verbal fluency as a function of 
`positive' and `negative' schizotypy. Personality and Individual Differences, 39, 705-713. 
Vardakou, I., Pistos, C. & Spiliopoulou, C. 2011. Drugs for youth via Internet and the example 
of mephedrone. Toxicology Letters, 201, 191-195. 
Vengeliene, V., Bilbao, A., Molander, A. & Spanagel, R. 2008. Neuropharmacology of alcohol 
addiction. British Journal of Pharmacology, 154, 299-315. 
Voglmaier, M. M., Seidman, L. J., Niznikiewicz, M. A., Dickey, C. C., Shenton, M. E. & 
Mccarley, R. W. 2005. A comparative profile analysis of neuropsychological function in 
Page 36 of 45
http://mc.manuscriptcentral.com/hup
Human Psychopharmacology: Clinical and Experimental
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 37 
men and women with schizotypal personality disorder. Schizophrenia Research, 74, 43-
49. 
Voglmaier, M. M., Seidman, L. J., Salisbury, D. & Mccarley, R. W. 1997. Neuropsychological 
dysfunction in schizotypal personality disorder: A profile analysis. Biological Psychiatry, 
41, 530-540. 
Vollema, M. G. & Postma, B. 2002. Neurocognitive Correlates of Schizotypy in First Degree 
Relatives of Schizophrenia Patients. Schizophrenia Bulletin, 28, 367-378. 
Walstab, J., Rappold, G. & Niesler, B. 2010. 5-HT3 receptors: Role in disease and target of 
drugs. Pharmacology & Therapeutics, 128, 146-169. 
Wendt, P. E. & Risberg, J. 2001. Ethanol Reduces rCFB Activation of Left Dorsolateral 
Prefrontal Cortex during a Verbal Fluency Task. Brain and Language, 77, 197-215. 
Wiens, A. N., Bryan, J. E. & Crossen, J. R. 1993. Estimating WAIS-R FSIQ from the National 
Adult Reading Test-Revised in normal subjects. Clinical Neuropsychologist, 7, 70-84. 
Winstock, A. R., Mitcheson, L. R., Deluca, P., Davey, Z., Corazza, O. & Schifano, F. 2011. 
Mephedrone, new kid for the chop? Addiction, 106, 154-161. 
Winterstein, B. P., Silvia, P. J., Kwapil, T. R., Kaufman, J. C., Reiter-Palmon, R. & Wigert, B. 
2011. Brief assessment of schizotypy: Developing short forms of the Wisconsin 
Schizotypy Scales. Personality and Individual Differences, 51, 920-924. 
Wood, A. G., Saling, M. M., Abbott, D. F. & Jackson, G. D. 2001. A neurocognitive account of 
frontal lobe involvement in orthographic lexical retrieval: An fMRI study. Neuroimage, 
14, 162-169. 
Wood, D. M. & Dargan, P. I. 2012. Mephedrone (4-methylmethcathinone): What is new in our 
understanding of its use and toxicity. Progress in Neuro-Psychopharmacology and 
Biological Psychiatry, 39, 227-233. 
Wood, D. M., Measham, F. & Dargan, P. I. 2012. ‘Our favourite drug’: prevalence of use and 
preference for mephedrone in the London night-time economy 1 year after control. 
Journal of Substance Use, 17, 91-97. 
Zammit, S., Lewis, G., Dalman, C. & Allebeck, P. 2010. Examining interactions between risk 
factors for psychosis. The British Journal of Psychiatry, 197, 207-211. 
Zeigler, D. W., Wang, C. C., Yoast, R. A., Dickinson, B. D., Mccaffree, M. A., Robinowitz, C. 
B. & Sterling, M. L. 2005. The neurocognitive effects of alcohol on adolescents and 
college students. Preventive Medicine, 40, 23-32. 
 
 
Page 37 of 45
http://mc.manuscriptcentral.com/hup
Human Psychopharmacology: Clinical and Experimental
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 38 
Tables 
Table 1. T-test values and descriptives for demographic variables, average sleep and total hours 
sleep between test sessions, BDI scores, schizotypy scores, and substance use in mephedrone 
users (n = 10 participants) and non-mephedrone using controls (n = 16 participants). Significant 
values are highlighted in bold. 
 
  Total   Mephedrone 
(N=10) 
Control 
(N=16) 
T-test 
statistics 
Variable Mean SD Mean SD Mean SD t(24) p 
Age 23.42 5.54 21.40 0.84 24.69 6.80 -1.91 0.07 
Verbal IQ 32.96 5.44 33.60 5.42 32.56 5.59 0.47 0.65 
Average hours sleep  7.58 1.03 7.60 1.06 7.56 1.03 0.09 0.93 
Total hours sleep between 
sessions 
19.35 4.99 19.80 4.10 19.06 5.58 0.36 0.72 
BDI
a
 pre
b
 8.15 7.25 11.90 5.53 5.81 7.36 2.24 0.03 
BDI post
c
 8.77 7.63 14.50 5.70 5.19 6.48 3.73 0.00 
UnEx
d
 3.35 2.71 4.60 2.41 2.56 2.66 1.97 0.06 
CogDis
e
 5.15 3.46 6.80 3.26 4.13 3.26 2.03 0.05 
IntAn
f
 1.73 1.80 2.00 1.89 1.56 1.79 0.59 0.56 
ImpNC
g
 3.42 2.48 5.30 1.57 2.25 2.24 3.76 0.00 
Amphetamine
 
past 30 days 0.19 0.49 0.50 0.71 0.00 0.00 2.24 0.05 
Mephedrone past 30 days 0.62 1.10 1.60 1.26 0.00 0.00 4.00 0.00 
Nicotine past 30 days 12.77 14.33 22.00 13.17 7.00 12.08 2.98 0.01 
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Cannabis past 30 days 2.31 4.35 4.80 6.12 0.75 1.53 2.05 0.07 
Alcohol past 30 days 9.62 6.54 9.20 5.29 9.88 7.37 -0.25 0.80 
Amphetamine past seven days 0.04 0.20 0.10 0.32 0.00 0.00 1.00 0.34 
Nicotine past seven days 2.96 3.36 5.00 3.23 1.69 2.85 2.74 0.01 
Cannabis past seven days 0.04 0.20 0.10 0.32 0.00 0.00 1.00 0.34 
Alcohol past seven days 1.54 1.61 1.30 1.49 1.69 1.70 -0.59 0.56 
Mephedrone between test 
sessions 
0.54 0.76 1.40 0.52 0.00 0.00 8.57 0.00 
Cannabis between test 
sessions 
0.27 1.00 0.70 1.57 0.00 0.00 1.41 0.19 
Alcohol between test sessions 16.08 7.03 20.50 7.75 13.31 5.02 2.88 0.01 
Age of first use: 
Amphetamine 18.75 1.86 19.00 1.66 18.00 2.65 0.79 0.45 
Age of first use: Mephedrone n/a n/a 20.67 0.50 n/a n/a n/a n/a 
Age of first use: Nicotine 16.00 3.12 15.38 1.19 16.63 4.31 -0.79 0.44 
Age of first use: Cannabis 17.56 4.06 16.60 1.78 18.75 5.75 -1.12 0.28 
Age of first use: Alcohol 14.85 1.93 14.70 1.57 14.94 2.17 -0.30 0.77 
 
Note: 
a 
Beck’s Depression Inventory; 
b 
Pre-clubbing experience; 
c 
Post-clubbing experience; 
d 
Unusual Experiences; 
e
 Cognitive Disorganisation; 
f 
Introvertive Anhedonia;
g
 Impulsive 
Nonconformity; 
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Table 2: Means and standard deviations (SD) of task performance for the total sample and the 
two groups separately. 
 All Mephedrone Control 
 Mean SD Mean SD Mean SD 
RAVLT
a
 % Immediate 
b 
pre
c
 
79.85 10.07 74.50 11.37 83.19 7.78 
RAVLT % Immediate 
post
 d
 
78.27 9.09 71.30 8.60 82.63 6.38 
RAVLT % Delayed
 e
 
pre 
82.81 17.03 74.60 19.39 87.94 13.60 
RAVLT % Delayed 
post 
82.27 19.27 66.00 19.18 92.44 10.54 
COWAT
f
 pre 45.88 9.09 42.40 10.29 48.06 7.81 
COWAT post 44.69 10.20 38.20 8.70 48.75 9.07 
TMT
 g
 index pre 16.49 9.39 14.61 5.80 17.66 11.10 
TMT index post 15.62 7.41 14.92 5.81 16.06 8.41 
Note: 
a 
Rey Auditory verbal memory task; 
b 
Immediate Recall; 
c
 Pre-clubbing; 
d 
Post-clubbing; 
e 
Delayed Recall; 
f
 Verbal Fluency Task; 
g 
Trail Making Task;  
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Table 3. Correlations between potential predictor variables and outcome measures pre- clubbing. 
Significant values are highlighted in bold. 
 
RAVLT
h
 % 
Immediate 
i 
pre 
RAVLT % 
Delayed
 j
 pre 
TMT
 k
 index 
pre COWAT
l
 pre 
Age 0.30 0.04 0.23 0.24 
NART
a
 0.15 0.08 -0.22 0.35† 
BDI
b
 pre
c
 -0.27 -0.26 -0.08 -0.34† 
Average sleep 0.05 0.29 -0.02 -0.16 
UnEx
d
 -0.22 -0.25 0.03 -0.25 
CogDis
e
 -0.47* -0.13 0.04 -0.65*** 
IntAn
f
 0.14 0.21 -0.13 0.17 
ImpNC
g
 -0.17 -0.17 0.09 -0.37† 
Amphetamine
 
 past seven days -0.32 -0.27 -0.28 -0.18 
Nicotine past seven days -0.23 -0.32 -0.18 0.21 
Cannabis past seven days -0.32 -0.27 -0.28 -0.18 
Alcohol past seven days -0.30 -0.15 -0.12 0.07 
Amphetamine
 
 past 30 days -0.49* -0.52** -0.21 -0.30 
Mephedrone past 30 days -0.48* -0.18 0.01 -0.29 
Nicotine past 30 days -0.21 -0.31 -0.18 0.04 
Cannabis past 30 days -0.63*** -0.34† 0.02 -0.39* 
Alcohol past 30 days 0.20 -0.07 -0.12 0.28 
 
†
p≤.10; * significant at p≤.05; ** significant at p≤.01; *** significant at p≤.001
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Note:
 a
 National Adult Reading Test; 
b 
Beck’s Depression Inventory; 
c
 Pre-clubbing experience; 
d
 
Unusual Experiences; 
e
 Cognitive Disorganization; 
f
 Introvertive Anhedonia; 
g
 Impulsive Non-
conformity; 
h
 Rey Auditory verbal memory task; 
i 
Immediate Recall; 
j 
Delayed Recall; 
k 
Trail 
Making Task; 
l
 Verbal Fluency Task; 
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Table 4. Correlations between potential predictor variables and outcome measures post-
clubbing. Significant values are highlighted in bold. 
 RAVLT
 h
 % 
Immediate
i 
post 
RAVLT % 
Delayed
 j
 
post 
TMT
 k
 
index 
post 
COWAT
l
 
post 
Age 0.32 0.04 0.07 0.36† 
NART
 a
 0.24 -0.02 -0.32 0.30 
BDI
 b
 post
c
 -0.49* -0.55** 0.02 -0.44* 
Total hours sleep 
between test sessions 
-0.36† -0.22 0.13 -0.39* 
UnEx
 d
 -0.31 -0.54** 0.09 -0.23 
CogDis
 e
 -0.52** -0.47* 0.15 -0.59** 
IntAn
 f
 -0.23 0.05 0.03 0.19 
ImpNC
 g
 -0.40* -0.47* 0.10 -0.40* 
Alcohol between test 
sessions 
0.02 -0.22 -0.06 -0.08 
Cannabis between 
test sessions 
-0.26 -0.35† -0.29 -0.29 
Mephedrone between 
test sessions 
-0.58** -0.52** 0.00 -0.43* 
†
p≤.10; * significant at p≤.05; ** significant at p≤.01; *** significant at p≤.001
 
 
 
Note: 
a
 National Adult Reading Test; 
b 
Beck’s Depression Inventory; 
c
 Post-clubbing; 
d
 Unusual 
Experiences; 
e
 Cognitive Disorganization; 
f
 Introvertive Anhedonia; 
g
 Impulsive Non-
conformity; 
h
 Rey Auditory verbal memory task; 
i 
Immediate Recall; 
j
 Delayed Recall; 
k 
Trail 
Making Task;
 l
 Verbal Fluency Task; 
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Table 5. Regression analysis assessing the effect of cannabis and amphetamine use (step 1) and 
CogDis (step 2) on cognitive functioning at the pre-clubbing session. Only significant ∆R²-values 
and their corresponding coefficients (β-values) are reported. 
Outcome 
variables 
Step Significant 
predictor 
β-value Total R² ∆R² F for ∆R² 
RAVLT
 a
 % 
immediate 
b
 
1 Cannabis -0.60* 0.48** 0.48** 6.85** 
  1 Amphetami
nes 
-0.33† 0.48** 0.48** 6.85** 
RAVLT % 
delayed 
c
 
1 Amphetami
nes 
-0.53* 0.35* .035* 3.99* 
COWAT
 d
 2 CogDis
 e
 -0.58** 0.45** 0.26** 9.76** 
† p≤.10; * significant at p≤.05; ** significant at p≤.01; *** significant at p≤.001
  
Note: 
a 
Rey Auditory verbal memory task; 
b 
Immediate Recall; 
c
 Delayed Recall; 
d
 Verbal 
Fluency Task; 
e
 Cognitive Disorganisation; 
 
Table 6. Regression assessing the effect of total hours of sleep between test sessions and 
depression (Beck´s Depression Inventory/BDI; step 1), mephedrone use between test sessions 
(step 2), and schizotypy (Unusual Experiences, Cognitive Disorganisation, and Impulsive Non-
conformity; step 3) on cognitive functioning post-clubbing. Only significant ∆R²-values and their 
corresponding coefficients (β-values) are reported. 
Outcome variables Step Significant 
predictor 
β-value Total R² ∆R² F for ∆R² 
RAVLT %
 a
 immediate 
b
 1 BDI
 e
 post
 f
  -0.55** 0.42** 0.42** 8.45** 
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1 Total hours 
of sleep 
between test 
sessions  
-0.43* 0.42** 0.42** 8.45** 
RAVLT
 
 % delayed 
c
 
1 BDI post -0.59** 0.39** 0.39** 7.40** 
COWAT
 d
 
1 BDI post -0.50** 0.39** 0.39** 7.49** 
 
1 Total hours 
of sleep 
between test 
sessions 
-0.46* 0.39** 0.39** 7.49** 
† p≤.10; * significant at p≤.05; ** significant at p≤.01; *** significant at p≤.001
  
Note: 
a 
Rey Auditory verbal memory task; 
b 
Immediate Recall; 
c
 Delayed Recall; 
d
 Verbal 
Fluency Task; 
e
 Beck’s Depression Inventory; 
f
 Post- clubbing; 
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